Today’s guest on the ValueTheMarkets podcast is Cathal Friel, CEO of Open Orphan. (LSE:ORPH) The company is focused on rare disease and orphan drug pharma services and aims to achieve rapid growth thorough the acquisition of smaller, high-margin pharma service providers. Open Orphan has just announced it has secured another new contract, this time with Carna Bioscience for a First In Human Clinical pharmacology trial.
The contract sees the Venn Life Sciences part of Open Orphan provide Carna with a range of expertise from chemistry manufacturing and controls to clinical trial management as well as biometry, legal and regulatory support.
In the interview, Cathal talks further about the deal and gives an update on progress of the integration of Venn Life Sciences which Open Orphan acquired via a reverse takeover earlier in the summer.
Author: Stuart Langelaan
Disclosure: The author was paid for this piece. The author does not own shares in the company mentioned.
All opinions expressed are those of ValueTheMarkets and the respective guests unless otherwise stated and should not be construed as investment advice or a recommendation to buy shares in any featured Company. Listeners are advised to do their own extensive research before buying shares which, as with all small-cap exploration stocks, should be viewed as high risk. Investors should also seek the advice of a qualified investment adviser or stockbroker as they deem appropriate.